Avenue Therapeutics, Inc. Stock Price

OTCPK:ATXI Community·US$2.4m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

Create a narrative

ATXI Share Price Performance

US$0.75

-1.25 (-62.50%)

US$0.75

-1.25 (-62.50%)

US$0.75

Sun, 9 Nov 25

Share PriceUS$0.75

ATXI Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

2 Rewards

View Full Analysis

Avenue Therapeutics, Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: 0.84
: 100.00%
: 190.38%
: 0%

View Full Analysis

About ATXI

Founded: 2015
Employees: 2
CEO: Alexandra MacLean
WebsiteView website: www.avenuetx.com

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.